IBB data by YCharts

Image placeholder title

October was the biotech sector's worst month in 2013.

"Worst" is relative in an otherwise unbelievable year for biotech stocks, but as you can see from the chart above, our little corner of the market was beat by the S&P 500 in October.

June was the only other month this year during which the S&P 500 outperformed the biotech sector, but the broader market just lost less.

Image placeholder title

IBB

data by

YCharts

There are many reasons for the recent weakness in biotech stocks. As the year ends, some investors have definitely decided to lighten up on their winners.

Catalyst Pharmaceuticals

(CPRX) - Get Report

was the best-performing stock between January and the end of September. And here's what Catalyst looked like in October:

Image placeholder title

^NBI

data by

YCharts

I probably had

something to do with the Catalyst sell off

.

Acadia Pharmaceuticals

(ACAD) - Get Report

was the second-best performing stock January through September. And in October:

Image placeholder title

ACAD

data by

YCharts

Celldex Therapeutics

(CLDX) - Get Report

: Third-best return January through September. Not in October: nd

Image placeholder title

CLDX

data by

YCharts

Picking up the pattern? Here's

Biocryst Pharmaceutics

(BCRX) - Get Report

, fourth best until Octoer:

Image placeholder title

^NBI

data by

YCharts

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on

Twitter

.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.